Lenvatinib

• Description :

  Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

• Product Name Alternative :

  E7080

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  C-Kit; FGFR; PDGFR; RET; VEGFR

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/lenvatinib.html

• Purity :

  99.75

• Solubility :

  DMSO : 12.5 mg/mL (ultrasonic)

• Smiles :

  O=C(N)C1=C(C=C2N=CC=C(C2=C1)OC3=CC=C(C(Cl)=C3)NC(NC4CC4)=O)OC

• Molecular Formula :

  C21H19ClN4O4

• Molecular Weight :

  426.85

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Kudo M, et al. Lenvatinib versus Bay 43-9006 in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391 (10126) :1163-1173.|[2]Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25 (1) :1073274818789361.|[3]Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122 (3), 664-671.|[4]Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14 (17),545.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4

• Citation 01 :

  Acta Derm Venereol. 2025 Apr 28:105:adv40697.|Acta Pharm. 2024 Sep 14;74 (3) :441-459.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Adv Healthc Mater. 2024 Nov;13 (29) :e2401398.|Adv Sci (Weinh) . 2024 Jul 9:e2402327.|Adv Sci (Weinh) . 2025 May 8:e2501730.|Am J Cancer Res. 2023 Nov 15;13 (11) :5368-5381.|Angiogenesis. 2025 Feb 3;28 (2) :13.|Ann Hepatol. 2025 Jun 1:101932.|Apoptosis. 2024 May 14.|Biochem Pharmacol. 2025 Jun 6:239:117032.|Biochem Pharmacol. 2025 Sep 26;242 (Pt 3) :117367.|Biodes Manuf. 17 July 2021.|Bioengineered. 2024 Dec;15 (1) :2296775.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Pharmacother. 2022 Jan;145:112391.|bioRxiv. 2023 Nov 17.|Cancer Biol Ther. 2025 Dec;26 (1) :2532217.|Cancer Cell Int. 2025 Oct 15;25 (1) :1-14.|Cancers (Basel) . 2023 Oct 22;15 (20) :5097.|Cancers (Basel) . 2025 Aug 29;17 (17) :2846.|Cancers (Basel) . 2025 Sep 9;17 (18) :2950.|Cell Death Dis. 2024 Jul 5;15 (7) :484.|Cell Death Discov. 2021 Nov 18;7 (1) :359.|Cell Oncol (Dordr) . 2024 Dec;47 (6) :2439-2460.|Cell Oncol (Dordr) . 2025 Apr;48 (2) :487-504.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Med. 2025 Jul 15;6 (7) :102208.|Cell Signal. 2023 Nov:111:110828.|Cell Signal. 2025 Nov:135:112067.|Drug Resist Updat. 2023 Jul:69:100976.|Ecotoxicol Environ Saf. 2024 Oct 15:285:117031.|EMBO J. 2021 Jun 1;40 (11) :e106771.|Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Front Biosci (Landmark Ed) . 2024 Jan 19;29 (1) :35.|Front Oncol. 2021 Jul 13:11:704042.|Front Oncol. 2022 Sep 8:12:944537.|Front Pharmacol. 2024 Apr 5.|Funct Integr Genomics. 2025 Nov 4;25 (1) :230.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Int Immunopharmacol. 2025 Mar 26:150:114278.|Int J Biol Macromol. 2026 Jan:336:149150.|Int J Biol Sci. 2023 Apr 23;19 (7) :2270-2288.|Int J Mol Sci. 2022 Sep 14;23 (18) :10677.|Int J Mol Sci. 2025 Apr 18;26 (8) :3829.|Int J Pharm X. 2025 Jun.|J Anal Test. 2025 Sep 25.|J Cell Mol Med. 2021 Jan;25 (1) :549-560.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100.|J Extracell Vesicles. 2024 Jul;13 (7) :e12468.|J Mol Neurosci. 2020 Sep;70 (9) :1437-1444.|J Oncol. 2022 Oct 18;2022:4537343.|J Transl Med. 2022 Mar 7;20 (1) :116.|J Transl Med. 2023 Jan 9;21 (1) :9.|Lasers Surg Med. 2024 Dec;56 (10) :845-853.|Liver Int. 2023 Jul;43 (7) :1577-1592.|Mar Drugs. 2024 Sep 28;22 (10) :444.|Med Oncol. 2021 Mar 17;38 (4) :41.|Med Oncol. 2020 Mar 12;37 (4) :24.|MedComm (2020) . 2022 Aug 26;3 (3) :e168.|Mol Med Rep. 2025 Nov;32 (5) :301.|Mol Ther. 2023 Jun 7;31 (6) :1829-1845.|Nat Commun. 2025 Nov 18;16 (1) :10096.|NPJ Precis Oncol. 2025 Aug 16;9 (1) :289.|Oncogene. 2024 Oct;43 (42) :3108-3120.|PeerJ. 2023 Jan 25:11:e14610.|Phytomedicine. 2024 Jul 25:130:155767.|Phytomedicine. 2025 May 10:143:156824.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Res Sq. 2024 Nov 18.|Research Square Preprint. 2021 May.|Research Square Preprint. 2023 Aug 5.|Research Square Print. 2022 Aug.|Research Square Print. 2022 May.|Research Square Print. 2023 Jan 9th, |Sci Rep. 2022 Jun 15;12 (1) :9951.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Signal Transduct Target Ther. 2025 Aug 1;10 (1) :244.|SSRN. 2023 Apr 24.|Transl Res. 2024 May 24:S1931-5244 (24) 00107-5.|ACS Appl Mater Interfaces. 2025 Jul 30;17 (30) :42893-42914.|Eur J Med Chem. 2025 Dec 6:303:118471.|J Exp Clin Cancer Res. 2025 Jan 11;44 (1) :11.|J Med Chem. 2024 Jul 11;67 (13) :10743-10773.

• CAS Number :

  [417716-92-8]